Category: Generative AI & LLMs
Off-the-shelf language models mishandle the terminology, abbreviations, and conventions of biomedical text — and the gap shows up exactly where precision matters most.
Biomedical text is its own dialect: dense abbreviations that mean different things in different subfields, drug names layered over brand names over compound codes, standardized terminologies with exact hierarchies, and conventions where a misread negation reverses clinical meaning. General-purpose language models, trained mostly on general text, handle this dialect unevenly — fluent on the surface, unreliable in the details that matter. Teams choosing language technology for pharma work face a real architecture question: when general models suffice, when domain adaptation is worth its cost, and how to tell the difference on their own data.
The failure points are systematic. Abbreviations are brutally ambiguous across specialties, and resolving them requires context a general model often lacks. Terminologies like coding dictionaries are not vocabulary but structured hierarchies with exact-match semantics — close is wrong. Negation and hedging carry the clinical meaning of a sentence, and misreading them inverts findings. Domain-adapted models and pipelines attack these directly: training on biomedical corpora, binding entity mentions to terminology standards, and building in the document conventions of clinical and regulatory text. The practical implication for buyers is that fluency is not evidence of competence. A general model produces confident prose about biomedical content while making exactly the errors — a mis-expanded abbreviation, a near-miss code, a missed negation — that matter most in this domain, which is why evaluation has to probe the details rather than the impression.
Build a test set from your own documents that concentrates the known hard cases: ambiguous abbreviations, negated findings, terminology-mapping tasks with exact-match scoring, and text from your specific therapeutic areas. Score exactly, not impressionistically — near-miss terminology mappings are errors, not partial credit. Compare a domain-adapted option against a well-prompted general model on the same set, because the size of the gap on your data, not the vendor's benchmark, is the number that should drive the decision. Ask vendors what their domain adaptation concretely consists of — training data, terminology binding, evaluation methodology — and how the system keeps current as terminologies release new versions. A credible answer is specific; a hand-wave toward the model being trained on medical text is not.
Teams usually discover this gap empirically — a pilot with a general model shows fluent output with domain errors in the details — so a structured comparison is the efficient next step: one representative task, one hard-case test set, general and domain-adapted options scored side by side. The result is a defensible basis for the architecture decision, and often a mixed one: general models for drafting and summarization, domain-adapted components where terminology precision and clinical meaning are load-bearing.
For tasks judged by human readers who catch domain slips — drafting assistance, summarization for review, internal search — well-prompted general models often perform respectably. The calculus changes where output feeds structured systems or must be exactly right: terminology coding, data extraction, and safety-relevant interpretation reward domain-adapted approaches.
Some combination of training or fine-tuning on biomedical text, binding entities to standard terminologies rather than free text, and building in the conventions of clinical and regulatory documents. Ask vendors to be specific about which of these they do and how they measure the result — the term is used loosely in the market.
It varies by task, which is why the honest answer comes from your own test set rather than published benchmarks. The gap tends to be smallest on fluent-prose tasks and largest on exact-match work like terminology mapping and negation-sensitive extraction — concentrate your evaluation there.
That is a common production pattern: general models handle drafting and summarization where fluency dominates, while domain-adapted components handle extraction, coding, and terminology work where precision dominates. The evaluation question becomes which components of your pipeline carry exact-match requirements.
Syntegra partnered with Datavant to connect its synthetic data engine with Datavant's de-identification and record-linking network, enabling privacy-preserving exchange of synthetic versions of linked real-world health datasets across the healthcare ecosystem.
Vendor: Syntegra · press release (Syntegra (GlobeNewswire)) · 2022-12-15 — Partner: Datavant
Abridge was named the first member of Epic's 'Pals' partnership program, integrating its generative-AI medical conversation summaries directly into Epic EHR workflows so health systems can adopt ambient documentation inside the tools clinicians already use.
Vendor: Abridge · press release (Abridge) · 2023-08-16 — Partner: Epic
Saama's AI-driven clinical analytics supported Pfizer's review of clinical trial data during its COVID-19 vaccine program; the companies subsequently expanded their relationship across Pfizer's broader R&D data operations.
Vendor: Saama Technologies · press release (Saama (Business Wire)) · 2024-02-12 — Partner: Pfizer
Kaiser Permanente rolled out Abridge's ambient AI clinical documentation technology across its integrated health system — 40 hospitals and more than 600 medical offices — letting clinicians generate draft visit notes from patient conversations instead of typing during encounters.
Vendor: Abridge · press release (Kaiser Permanente) · 2024-08-14 — Partner: Kaiser Permanente
A quality-improvement survey at the University of Kansas Medical Center, published in JAMIA Open, reported that clinicians using Abridge's ambient AI documentation self-reported lower perceived work burden and burnout and higher job satisfaction after implementation. Vendor-affiliated authors participated in the study.
Vendor: Abridge · peer reviewed (JAMIA Open (Oxford University Press)) · 2025-02-21